Literature DB >> 33926566

Are researchers getting the terms used to denote different types of recreational cannabis right?-a user perspective.

Ava Mason1, Musa Sami2, Caitlin Notley3, Sagnik Bhattacharyya4.   

Abstract

BACKGROUND: While current cannabis research has advanced our understanding into the effects of its individual components, there is a pressing need to identify simple terminology that is understood in the same way by researchers and users of cannabis. Current categorisation in research focuses on the two main cannabinoids: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD); and two different species of cannabis: indica and sativa. Recreational cannabis has also been categorised by researchers as 'skunk' or 'hash'. Focusing on individuals who use cannabis frequently, this study aimed to identify views on current terms used to denote different types of cannabis and to identify terms validated by participants. These views were extracted from responses of the Cannabis Experiences Questionnaire (CEQ), a widely used instrument in the literature.
METHODS: We qualitatively analysed 236 free-text responses from Question 23 of the CEQ survey (using Iterative Categorisation) relating to categorization and consumption methods. Data was used from a previous study (Sami et al., Psychol Med 49:103-12, 2019), which recruited a convenience sample of 1231 participants aged 18 years and above who had previously used cannabis.
RESULTS: Regarding type of cannabis used, specific strain names (n = 130), concentrates (n = 37), indica/sativa (n = 22) and THC/CBD terms (n = 22) were mentioned. Other terms used were hybrids (n = 10), origins of specific strains (n = 17), edibles (n = 8), and herbal cannabis (n = 7). Regarding problems with specific terms, participants were skeptical about terms such as skunk and super skunk (n = 78) preferring terms like THC/CBD, indica/sativa, specific marketed strains and references to preparation methods.
CONCLUSIONS: The results suggest a disparity between the common terms used by researchers in academia and those used by cannabis consumers. While there are advantages and limitations of using these terms to bridge views of researchers and individuals who use cannabis, this study underscores the importance of formally assessing chemical constituents rather than relying on self-report data and of incorporating cannabis user views on current terms used in research, potentially also incorporating descriptors of preparation and consumption methods.

Entities:  

Keywords:  Cannabis; Cannabis terms; Skunk; Cannabis users; Iterative categorisation

Year:  2021        PMID: 33926566     DOI: 10.1186/s42238-021-00065-1

Source DB:  PubMed          Journal:  J Cannabis Res        ISSN: 2522-5782


  22 in total

1.  Cannabis-induced psychosis-like experiences are associated with high schizotypy.

Authors:  E J Barkus; J Stirling; R S Hopkins; S Lewis
Journal:  Psychopathology       Date:  2006-04-12       Impact factor: 1.944

2.  Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users.

Authors:  Marcel O Bonn-Miller; Matthew Tyler Boden; Meggan M Bucossi; Kimberly A Babson
Journal:  Am J Drug Alcohol Abuse       Date:  2013-11-08       Impact factor: 3.829

3.  Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

Authors:  Marta Di Forti; Arianna Marconi; Elena Carra; Sara Fraietta; Antonella Trotta; Matteo Bonomo; Francesca Bianconi; Poonam Gardner-Sood; Jennifer O'Connor; Manuela Russo; Simona A Stilo; Tiago Reis Marques; Valeria Mondelli; Paola Dazzan; Carmine Pariante; Anthony S David; Fiona Gaughran; Zerrin Atakan; Conrad Iyegbe; John Powell; Craig Morgan; Michael Lynskey; Robin M Murray
Journal:  Lancet Psychiatry       Date:  2015-02-25       Impact factor: 27.083

4.  Validation of the Cannabis Expectancy Questionnaire (CEQ) in adult cannabis users in treatment.

Authors:  Jason P Connor; Matthew J Gullo; Gerald F X Feeney; Ross McD Young
Journal:  Drug Alcohol Depend       Date:  2010-12-16       Impact factor: 4.492

5.  Minor oxygenated cannabinoids from high potency Cannabis sativa L.

Authors:  Safwat A Ahmed; Samir A Ross; Desmond Slade; Mohamed M Radwan; Ikhlas A Khan; Mahmoud A ElSohly
Journal:  Phytochemistry       Date:  2015-06-17       Impact factor: 4.072

6.  High-potency cannabis and the risk of psychosis.

Authors:  Marta Di Forti; Craig Morgan; Paola Dazzan; Carmine Pariante; Valeria Mondelli; Tiago Reis Marques; Rowena Handley; Sonija Luzi; Manuela Russo; Alessandra Paparelli; Alexander Butt; Simona A Stilo; Ben Wiffen; John Powell; Robin M Murray
Journal:  Br J Psychiatry       Date:  2009-12       Impact factor: 9.319

7.  Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

Authors:  Sagnik Bhattacharyya; Paul D Morrison; Paolo Fusar-Poli; Rocio Martin-Santos; Stefan Borgwardt; Toby Winton-Brown; Chiara Nosarti; Colin M O' Carroll; Marc Seal; Paul Allen; Mitul A Mehta; James M Stone; Nigel Tunstall; Vincent Giampietro; Shitij Kapur; Robin M Murray; Antonio W Zuardi; José A Crippa; Zerrin Atakan; Philip K McGuire
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

8.  Vaping cannabis (marijuana): parallel concerns to e-cigs?

Authors:  Alan J Budney; James D Sargent; Dustin C Lee
Journal:  Addiction       Date:  2015-08-12       Impact factor: 6.526

Review 9.  Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.

Authors:  Marco Colizzi; Sagnik Bhattacharyya
Journal:  Curr Addict Rep       Date:  2017-04-29

10.  Differences in cannabis-related experiences between patients with a first episode of psychosis and controls.

Authors:  F Bianconi; M Bonomo; A Marconi; A Kolliakou; S A Stilo; C Iyegbe; P Gurillo Muñoz; S Homayoun; V Mondelli; S Luzi; P Dazzan; D Prata; C La Cascia; J O'Connor; A David; C Morgan; R M Murray; M Lynskey; M Di Forti
Journal:  Psychol Med       Date:  2015-12-16       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.